Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

rs641738C>T nearMBOAT7is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

  • Teo, Kevin
  • Abeysekera, Kushala W.M.
  • Adams, Leon
  • Aigner, Elmar
  • Anstee, Quentin M.
  • Bañales Asurmendi, Jesús María
  • Banerjee, Rajarshi
  • Basu, Priyadarshi
  • Berg, Thomas
  • Bhatnagar, Pallav
  • Buch, Stephan
  • Canbay, Ali
  • Caprio, Sonia
  • Chatterjee, Ankita
  • Chen, Yii-Der Ida
  • Chowdhury, Abhijit
  • Daly, Ann K.
  • Datz, Christian
  • De Gracia Hahn, Dana
  • DiStefano, Johanna K.
  • Dong, Jiawen
  • Duret, Amedine
  • EU-PNAFLD Investigators
  • Emdin, Connor
  • Fairey, Madison
  • Gerhard, Glenn S.
  • GOLD Consortium
  • Guo, Xiuqing
  • Hampe, Jochen
  • Hickman, Matthew
  • Heintz, Lena
  • Hudert, Christian
  • Hunter, Harriet
  • Kelly, Matt
  • Kozlitina, Julia
  • Krawczyk, Marcin
  • Lammert, Frank
  • Langenberg, Claudia
  • Lavine, Joel
  • Li, Lin
  • Lim, Hong Kai
  • Loomba, Rohit
  • Luukkonen, Panu K.
  • Melton, Phillip E.
  • Mori, Trevor A.
  • Palmer, Nicholette D.
  • Parisinos, Constantinos A.
  • Pillai, Sreekumar G.
  • Qayyum, Faiza
  • Reichert, Matthias C.
  • Romeo, Stefano
  • Rotter, Jerome I.
  • Im, Yu Ri
  • Santoro, Nicola
  • Schafmayer, Clemens
  • Speliotes, Elizabeth K.
  • Stender, Stefan
  • Stickel, Felix
  • Still, Christopher D.
  • Strnad, Pavel
  • Taylor, Kent D.
  • Tybjærg-Hansen, Anne
  • Umano, Giuseppina Rosaria
  • Utukuri, Mrudula
  • Valenti, Luca
  • Wagenknecht, Lynne E.
  • Wareham, Nicholas J.
  • Watanabe, Richard M.
  • Wattacheril, Julia
  • Yaghootkar, Hanieh
  • Yki-Järvinen, Hannele
  • Young, Kendra A.
  • Mann, Jake P.
Background & Aims: A common genetic variant near MBOAT7 (rs641738C>T) has been previously associated with hepatic fat and advanced histology in NAFLD; however, these findings have not been consistently replicated in the literature. We aimed to establish whether rs641738C>T is a risk factor across the spectrum of NAFLD and to characterise its role in the regulation of related metabolic phenotypes through a meta-analysis. Methods: We performed a meta-analysis of studies with data on the association between rs641738C>T genotype and liver fat, NAFLD histology, and serum alanine aminotransferase (ALT), lipids or insulin. These included directly genotyped studies and population-level data from genome-wide association studies (GWAS). We performed a random effects meta-analysis using recessive, additive and dominant genetic models. Results: Data from 1,066,175 participants (9,688 with liver biopsies) across 42 studies were included in the meta-analysis. rs641738C>T was associated with higher liver fat on CT/MRI (+0.03 standard deviations [95% CI 0.02-0.05], p(z) = 4.8x10(-5)) and diagnosis of NAFLD (odds ratio [OR] 1.17 [95% CI 1.05-1.3], p(z) = 0.003) in Caucasian adults. The variant was also positively associated with presence of advanced fibrosis (OR 1.22 [95% CI 1.03-1.45], p(z) = 0.021) in Caucasian adults using a recessive model of inheritance (CC + CT vs. TT). Meta-analysis of data from previous GWAS found the variant to be associated with higher ALT (p(z) = 0.002) and lower serum triglycerides (p(z) = 1.5x10(-4)). rs641738C>T was not associated with fasting insulin and no effect was observed in children with NAFLD. Conclusions: Our study validates rs641738C>T near MBOAT7 as a risk factor for the presence and severity of NAFLD in individuals of European descent. Lay summary: Fatty liver disease is a common condition where fat builds up in the liver, which can cause liver inflammation and scarring (including 'cirrhosis'). It is closely linked to obesity and diabetes, but some genes are also thought to be important. We did this study to see whether one specific change ('variant') in one gene ('MBOAT7') was linked to fatty liver disease. We took data from over 40 published studies and found that this variant near MBOAT7 is linked to more severe fatty liver disease. This means that drugs designed to work on MBOAT7 could be useful for treating fatty liver disease., J.P.M. is supported by a Wellcome Trust Fellowship (216329/Z/19/Z), a European Paediatric Research Society award and a Children's Liver Disease Foundation grant. The EU-PNAFLD is supported by an EASL Registry Grant. NIH grants: R01HD028016 (S.C.), R01DK111038 (S.C)., R01DK114504 (N.S.), DK091601 (J.K.D.) and UL1TR001105 (J.K.). Supported by the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, and U01DK061713); the National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448, UL1TR000100, UL1TR000004, UL1TR000423, UL1TR000058, and UL1TR001881); and the NIDDK (DK063491 to the Southern California Diabetes Endocrinology Research Center). This study was supported by the German Federal Ministry for Education and Research (BmBF) through the Livers Systems Medicine (LiSyM) project. This work was supported by grants from the Swiss National Funds (SNF no. 310030_169196) and the Swiss Foundation for Alcohol Research (SSA) to F.S. This Raine Study was supported by the National Health and Medical Research Council of Australia (grant numbers 403981, 353514 and 572613). The UK Medical Research Council and Wellcome (grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. ALSPAC GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (www.bristol.ac.uk/alspac/external/documents/grant-acknowledgemen ts.pdf); this research was specifically funded by grants from MRC and Alcohol Research UK (MR/L022206/1) and NIH (5R01AA018333-05) to K.W.M.A. and M.H. L.V. was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. German Federal Ministry of Education and Research (BMBF LiSyM 031L0051 to F.L.). P.L. is supported by grants from the Sigrid Juselius Foundation and the Novo Nordisk Foundation. The Fenland study was funded by grants to the MRC Epidemiology Unit (MC UU12015/1, MC UU 12015/5). R.B. and M.K. are employees of and shareholders in Perspectum Diagnostics Ltd. C.A.P. is funded by aWellcome Trust Clinical PhD Programme (206274/Z/17/Z). J.M.B. is supported by the Spanish Carlos III Health Institute (ISCIII; PI15/01132, PI18/01075, CIBERehd, and Miguel Servet Program CON14/00129) cofinanced by Fondo Europeo de Desarrollo Regional (FEDER) and La Caixa Scientific Foundation (HR17-00601). Research from the GUARDIAN Study was supported DK085175 and DK118062, and phenotyping in IRASFS was supported by HL060944, HL061019, HL060919 and HL060894 IRASFS from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). H.Y. is funded by a Diabetes UK RD Lawrence fellowship (17/0005594). Q.M.A. and A.D. supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413. Q.M.A., A.D., L.V. and A.G. are members of the LITMUS (Liver Investigation: Testing Biomarker Utility in Steatohepatitis) consortium funded by the European Union Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement 777377. Q.M.A.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

P465L pparγ mutation confers partial resistance to the hypolipidemic action of fibrates.

  • Rodriguez Cuenca, Sergio
  • Carobbio, Stefania
  • Barceló-Coblijn, Gwendolyn
  • Prieur, Xavier
  • Relat Pardo, Joana
  • Amat, Ramon
  • Campbell, Mark
  • Dias, Ana Rita
  • Bahri, Myriam
  • Gray, Sarah L.
  • Vidal-Puig, Antonio
Familial partial lipodystrophic syndrome 3 (FPLD3) is associated with mutations in the transcription factor PPAR. The P467L mutant confers a dominant negative effect. We have previously investigated the pathophysiology of FPLD3 using a humanised mouse harbouring an equivalent mutation (P465L) in PPAR that recapitulated the human clinical phenotype. One of the key clinical manifestations observed in humans and mice is the accumulation of fat in the liver. Here, we dissect the molecular mechanisms that facilitate accumulation of lipids in the liver and characterise the negative effect of the PPAR mutation on the activation of PPAR in vivo by fibrates. P465L mice have increased insulin and FFAs, decreased secretion of VLDL when fed HFD and impaired hypolipidemic response to WY14643. Thus, the phenotype of PPAR mutations may synergise with defects on PPAR function, indicating that the phenotype of the FPLD3 patients may not only be attributed to the dysfunction of PPAR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The impact of human activities and lifestyles on the interlinked microbiota and health of humans and of ecosystems

  • Flandroy, L.
  • Poutahidis, T.
  • Berg, Gabriele
  • Clarke, Gerard
  • Dao, M.C.
  • Decaestecker, E.
  • Furman, E.
  • Haahtela, T.
  • Massart, S.
  • Plovier, H.
  • Sanz Herranz, Yolanda
  • Rook, G.
Plants, animals and humans, are colonized by microorganisms (microbiota) and transiently exposed to countless others. The microbiota affects the development and function of essentially all organ systems, and contributes to adaptation and evolution, while protecting against pathogenic microorganisms and toxins. Genetics and lifestyle factors, including diet, antibiotics and other drugs, and exposure to the natural environment, affect the composition of the microbiota, which influences host health through modulation of interrelated physiological systems. These include immune system development and regulation, metabolic and endocrine pathways, brain function and epigenetic modification of the genome. Importantly, parental microbiotas have transgenerational impacts on the health of progeny. Humans, animals and plants share similar relationships with microbes. Research paradigms from humans and other mammals, amphibians, insects, planktonic crustaceans and plants demonstrate the influence of environmental microbial ecosystems on the microbiota and health of organisms, and indicate links between environmental and internal microbial diversity and good health. Therefore, overlapping compositions, and interconnected roles of microbes in human, animal and plant health should be considered within the broader context of terrestrial and aquatic microbial ecosystems that are challenged by the human lifestyle and by agricultural and industrial activities. Here, we propose research priorities and organizational, educational and administrative measures that will help to identify safe microbe-associated health-promoting modalities and practices. In the spirit of an expanding version of “One health” that includes environmental health and its relation to human cultures and habits (EcoHealth), we urge that the lifestyle-microbiota-human health nexus be taken into account in societal decision making., GC's attendance at the workshop was supported by the APC Microbiome Institute via Science Foundation Ireland funding (Grant number SFI/12/RC/2273). ED was supported by FWO grant G.0643.13. GB was funded by the European Union (BIOCOMES; 612713) and by the Austrian and Styrian Science Fund (FWF; P29285-BBL). M-CD received funding from the Programme for Research, Technological Development and Demonstration under grant agreement HEALTH-F4-2012-305312 (METACARDIS) and Horizon 2020 Framework Programme (EPoS, grant #634413) as well as Assistance Publique Hôpitaux de Paris. HP is a research fellow at FRS-FNRS, Belgium. The contribution of YS is supported by the European Union's Seventh Framework Program under the grant agreement no 613979 (MyNewGut)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR

  • Metwally, Mayada
  • Bayoumi, Ali
  • Romero-Gómez, Manuel
  • Thabet, Khaled
  • John, Miya
  • Adams, Leon A.
  • Huo, Xiaoqi
  • Aller, Rocío
  • García-Monzón, Carmelo
  • Arias-Loste, María Teresa
  • Bugianesi, Elisabetta
  • Miele, Luca
  • Gallego-Durán, Rocío
  • Fischer, Janett
  • Berg, Thomas
  • Liddle, Christopher
  • Qiao, Liang
  • George, Jacob
  • Eslam, Mohammed
[Background & Aims] Irisin, the cleaved extra-cellular fragment of the Fibronectin type III domain-containing protein 5 (FNDC5) is a myokine that is proposed to have favorable metabolic activity. We aimed to elucidate the currently undefined role of variants in the FNDC5 gene in non-alcoholic fatty liver disease (NAFLD). Methods We prioritized single nucleotide polymorphisms in FNDC5 on the basis of their putative biological function and identified rs3480 in the 3′ untranslated region (3′UTR). We studied the association of rs3480 with liver disease severity and the metabolic profile of 987 Caucasian patients with NAFLD. Functional investigations were undertaken using luciferase reporter assays of the 3′UTR of human FNDC5, pyrosequencing for allele-specific expression of FNDC5 in liver, measurement of serum irisin, and bioinformatics analysis. Results The rs3480 (G) allele was associated with advanced steatosis (OR 1.29; 95% CI 1.08–1.55; p = 0.004), but not with other histological features. This effect was independent but additive to PNPLA3 and TM6SF2. The rs3480 polymorphism influenced FNDC5 mRNA stability and the binding of miR-135a-5P. Compared with controls, hepatic expression of this microRNA was upregulated while FNDC5 expression was downregulated. Elevated serum irisin was associated with reduced steatosis, and an improved metabolic profile. Conclusions Carriage of the FNDC5 rs3480 minor (G) allele is associated with more severe steatosis in NAFLD through a microRNA-mediated mechanism controlling FNDC5 mRNA stability. Irisin is likely to have a favorable metabolic impact on NAFLD. Lay summary Irisin is a novel protein produced mainly by muscle, which is known to be released into the circulation, with an unclear role in liver fat deposition. This study demonstrates that genetic variants in the gene encoding the irisin protein modulate the risk of liver fat in patients with fatty liver disease. Interestingly, these effects are independent of, but additive to those of other recently described genetic variants that contribute to liver fat. In functional studies, we have deciphered the detailed molecular mechanisms by which this genetic variant mediates its effects., [Methods] We prioritized single nucleotide polymorphisms in FNDC5 on the basis of their putative biological function and identified rs3480 in the 3′ untranslated region (3′UTR). We studied the association of rs3480 with liver disease severity and the metabolic profile of 987 Caucasian patients with NAFLD. Functional investigations were undertaken using luciferase reporter assays of the 3′UTR of human FNDC5, pyrosequencing for allele-specific expression of FNDC5 in liver, measurement of serum irisin, and bioinformatics analysis., [Results] The rs3480 (G) allele was associated with advanced steatosis (OR 1.29; 95% CI 1.08–1.55; p = 0.004), but not with other histological features. This effect was independent but additive to PNPLA3 and TM6SF2. The rs3480 polymorphism influenced FNDC5 mRNA stability and the binding of miR-135a-5P. Compared with controls, hepatic expression of this microRNA was upregulated while FNDC5 expression was downregulated. Elevated serum irisin was associated with reduced steatosis, and an improved metabolic profile., [Conclusions] Carriage of the FNDC5 rs3480 minor (G) allele is associated with more severe steatosis in NAFLD through a microRNA-mediated mechanism controlling FNDC5 mRNA stability. Irisin is likely to have a favorable metabolic impact on NAFLD., [Lay summary] Irisin is a novel protein produced mainly by muscle, which is known to be released into the circulation, with an unclear role in liver fat deposition. This study demonstrates that genetic variants in the gene encoding the irisin protein modulate the risk of liver fat in patients with fatty liver disease. Interestingly, these effects are independent of, but additive to those of other recently described genetic variants that contribute to liver fat. In functional studies, we have deciphered the detailed molecular mechanisms by which this genetic variant mediates its effects., ME and JG are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206, APP1149976) and Project grants (APP1107178 and APP1108422). AB is supported by an Australian Government Research Training Program (RTP) scholarship. EB is supported by Horizon 2020 under grant 634413 for the project EPoS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease

  • Bayoumi, Ali
  • Jalil, Ismail
  • Metwally, Mayada
  • Adams, Leon A.
  • Aller, Rocío
  • García-Monzón, Carmelo
  • Arias-Loste, María Teresa
  • Miele, Luca
  • Petta, Salvatore
  • Craxi, Antonio
  • Gallego-Durán, Rocío
  • Fischer, Janett
  • Berg, Thomas
  • Qiao, Liang
  • Liddle, Christopher
  • Bugianesi, Elisabetta
  • Romero-Gómez, Manuel
  • George, Jacob
  • Eslam, Mohammed
Metabolic associated fatty liver disease (MAFLD) is the most prevalent liver disease in Western nations, with high heritability. A recent study of Japanese patients with the disease suggested that TLL1 rs17047200 is associated with fibrosis; whether a similar association is observed in Caucasian patients with MAFLD is unknown. We investigated the association of the TLL1 rs17047200 polymorphism with liver fibrosis in a cohort of Caucasian patients with MAFLD (n = 728). We also investigated whether TLL1 expression is altered during liver injury in humans, in murine models of fibrosis, and in in-vitro. While TLL1 expression is upregulated in the liver of humans with MAFLD and in mice, the rs17047200 variant was not associated with fibrosis or any other histological features, or with hepatic TLL1 expression. In conclusion, the TLL1 rs17047200 variant is not a risk variant for fibrosis in Caucasian patients with MAFLD. However, TLL1 could be involved in the pathogenesis of liver fibrosis., ME and JG are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; National Health and Medical Research Council of Australia (NHMRC) Program Grants (1053206 and 1149976) and Project grants (1107178 and 1108422). EB is supported by Horizon 2020 under grant 634413 for the project EPoS. AB is supported by an Australian Government Research Training Program (RTP) scholarship.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

  • Hardy, Timothy
  • Wonders, Kristy
  • Younes, Ramy
  • Aithal, Guruprasad P.
  • Aller, Rocío
  • Allison, Michael
  • Bedossa, Pierre
  • Betsou, Fay
  • Boursier, Jerome
  • Brosnan, M. Julia
  • Burt, Alastair
  • Cobbold, Jeremy
  • Cortez-Pinto, Helena
  • Day, Chris P.
  • Dufour, Jean-François
  • Ekstedt, Mattias
  • Francque, Sven
  • Harrison, Stephen A.
  • Miele, Luca
  • Nasr, Patrik
  • Papatheodoridis, George
  • Petta, Salvatore
  • Tiniakos, Dina
  • Torstenson, Richard
  • Valenti, Luca
  • Holleboom, Adriaan G.
  • Yki-Järvinen, Hannele
  • Geier, Andreas
  • Romero-Gómez, Manuel
  • Ratziu, Vlad
  • Bugianesi, Elisabetta
  • Schattenberg, Jörn M.
  • Anstee, Quentin M.
© 2020 The Author(s)., Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There is significant variability in the disease course: the majority exhibit only fat accumulation in the liver but a significant minority develop a necroinflammatory form of the disease (non-alcoholic steatohepatitis, NASH) that may progress to cirrhosis and hepatocellular carcinoma. At present our understanding of pathogenesis, disease natural history and long-term outcomes remain incomplete. There is a need for large, well characterised patient cohorts that may be used to address these knowledge gaps and to support the development of better biomarkers and novel therapies. The European NAFLD Registry is an international, prospectively recruited observational cohort study that aims to establish a large, highly-phenotyped patient cohort and linked bioresource. Here we describe the infrastructure, data management and monitoring plans, and the standard operating procedures implemented to ensure the timely and systematic collection of high-quality data and samples. Already recruiting subjects at secondary/tertiary care centres across Europe, the Registry is supporting the European Union IMI2-funded LITMUS ‘Liver Investigation: Testing Marker Utility in Steatohepatitis’ consortium, which is a major international effort to robustly validate biomarkers that diagnose, risk stratify and/or monitor NAFLD progression and liver fibrosis stage. The European NAFLD Registry has the demonstrable capacity to support research and biomarker development at scale and pace., The European NAFLD Registry is supported by the LITMUS (Liver Investigation: Testing Biomarker Utility in Steatohepatitis) consortium funded by the European Union Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement 777377, which receives support from the Horizon 2020 Framework Program of European Union and EFPIA. It has also received support from the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413, the FLIP consortium funded by the Framework Program 7 of the European Union under grant agreement 241762, and an EASL Registry Grant from the European Association for the Study of the Liver.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

  • Younes, Ramy
  • Caviglia, Gian Paolo
  • Govaere, Olivier
  • Rosso, Chiara
  • Armandi, Angelo
  • Sanavia, tiziana
  • Pennisi, Grazia
  • Liguori, Antonio
  • Francione, Paolo
  • Gallego-Durán, Rocío
  • Ampuero, Javier
  • García Blanco, María J.
  • Aller, Rocío
  • Tiniakos, Dina
  • Burt, Alastair
  • David, Ezio
  • Vecchio, Fabio Maria
  • Maggioni, Marco
  • Cabibi, Daniela
  • Pareja, María Jesús
  • Zaki, Marco Y. W.
  • Grieco, Antonio
  • Fracanzani, Anna Ludovica
  • Valenti, Luca
  • Miele, Luca
  • Fariselli, Piero
  • Petta, Salvatore
  • Romero-Gómez, Manuel
  • Anstee, Quentin M.
  • Bugianesi, Elisabetta
[Background & Aims] Non-invasive scoring systems (NSS) are used to identify patients with non-alcoholic fatty liver disease (NAFLD) who are at risk of advanced fibrosis, but their reliability in predicting long-term outcomes for hepatic/extrahepatic complications or death and their concordance in cross-sectional and longitudinal risk stratification remain uncertain., [Methods] The most common NSS (NFS, FIB-4, BARD, APRI) and the Hepamet fibrosis score (HFS) were assessed in 1,173 European patients with NAFLD from tertiary centres. Performance for fibrosis risk stratification and for the prediction of long-term hepatic/extrahepatic events, hepatocarcinoma (HCC) and overall mortality were evaluated in terms of AUC and Harrell’s c-index. For longitudinal data, NSS-based Cox proportional hazard models were trained on the whole cohort with repeated 5-fold cross-validation, sampling for testing from the 607 patients with all NSS available., [Results] Cross-sectional analysis revealed HFS as the best performer for the identification of significant (F0-1 vs. F2-4, AUC = 0.758) and advanced (F0-2 vs. F3-4, AUC = 0.805) fibrosis, while NFS and FIB-4 showed the best performance for detecting histological cirrhosis (range AUCs 0.85-0.88). Considering longitudinal data (follow-up between 62 and 110 months), NFS and FIB-4 were the best at predicting liver-related events (c-indices>0.7), NFS for HCC (c-index = 0.9 on average), and FIB-4 and HFS for overall mortality (c-indices >0.8). All NSS showed limited performance (c-indices <0.7) for extrahepatic events., [Conclusions] Overall, NFS, HFS and FIB-4 outperformed APRI and BARD for both cross-sectional identification of fibrosis and prediction of long-term outcomes, confirming that they are useful tools for the clinical management of patients with NAFLD at increased risk of fibrosis and liver-related complications or death., [Lay summary] Non-invasive scoring systems are increasingly being used in patients with non-alcoholic fatty liver disease to identify those at risk of advanced fibrosis and hence clinical complications. Herein, we compared various non-invasive scoring systems and identified those that were best at identifying risk, as well as those that were best for the prediction of long-term outcomes, such as liver-related events, liver cancer and death., This study has been supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413 and the Newcastle NIHR Biomedical Research Centre. The authors are contributing members of The European NAFLD Registry. The study was also supported by the Italian Ministry of Health, grant RF-2016-02364358 (Ricerca Finalizzata, Ministero della Salute), and the Italian Ministry for Education, University and Research (Ministero dell’Istruzione, dell’Università e della Ricerca - MIUR) under the programme “Dipartimenti di Eccellenza 2018 – 2022” Project code D15D18000410001., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus

  • Bayoumi, Ali
  • Elsayed, Asmaa
  • Han, Shuanglin
  • Petta, Salvatore
  • Adams, Leon A.
  • Aller, Rocío
  • Khan, Anis
  • García-Monzón, Carmelo
  • Arias-Loste, María Teresa
  • Miele, Luca
  • Latchoumanin, Olivier
  • Alenizi, Shafi
  • Gallego-Durán, Rocío
  • Fischer, Janett
  • Berg, Thomas
  • Craxi, Antonio
  • Metwally, Mayada
  • Qiao, Liang
  • Liddle, Christopher
  • Yki-Järvinen, Hannele
  • Bugianesi, Elisabetta
  • Romero-Gómez, Manuel
  • George, Jacob
  • Eslam, Mohammed
This article also appears in: Health, Medical, and Life Sciences Virtual Issue for Advanced Science., Fibroblast growth factor 21 (FGF21) is a liver-derived hormone with pleiotropic beneficial effects on metabolism. Paradoxically, FGF21 levels are elevated in metabolic diseases. Interventions that restore metabolic homeostasis reduce FGF21. Whether abnormalities in FGF21 secretion or resistance in peripheral tissues is the initiating factor in altering FGF21 levels and function in humans is unknown. A genetic approach is used to help resolve this paradox. The authors demonstrate that the primary event in dysmetabolic phenotypes is the elevation of FGF21 secretion. The latter is regulated by translational reprogramming in a genotype- and context-dependent manner. To relate the findings to tissues outcomes, the minor (A) allele of rs838133 is shown to be associated with increased hepatic inflammation in patients with metabolic associated fatty liver disease. The results here highlight a dominant role for translation of the FGF21 protein to explain variations in blood levels that is at least partially inherited. These results provide a framework for translational reprogramming of FGF21 to treat metabolic diseases., M.E. and J.G. were supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206) and Project and ideas grants (APP2001692, APP1107178 and APP1108422). A.B. was supported by an Australian Government Research Training Program (RTP) scholarship. E.B. was supported by Horizon 2020 under grant 634413 for the project EPoS.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease

  • Metwally, Mayada
  • Bayoumi, Ali
  • Khan, Anis
  • Adams, Leon A.
  • Aller, Rocío
  • García-Monzón, Carmelo
  • Arias-Loste, María Teresa
  • Bugianesi, Elisabetta
  • Miele, Luca
  • Alisi, Anna
  • Latchoumanin, Olivier
  • Han, Shuanglin
  • Alenizi, Shafi
  • El Sharkawy, Rasha
  • Elattar, Afaf
  • Gallego-Durán, Rocío
  • Fischer, Janett
  • Berg, Thomas
  • Liddle, Christopher
  • Romero-Gómez, Manuel
  • George, Jacob
  • Eslam, Mohammed
[Background] Liver fibrosis risk is a heritable trait, the outcome of which is the net deposition of extracellular matrix by hepatic stellate cell-derived myofibroblasts. Whereas nucleotide sequence variations have been extensively studied in liver fibrosis, the role of copy number variations (CNV) in which genes exist in abnormal numbers of copies (mostly due to duplication or deletion) has had limited exploration., [Methods] The impact of the XPO4 CNV on histological liver damage was examined in a cohort comprised 646 Caucasian patients with biopsy-proven MAFLD and 170 healthy controls. XPO4 expression was modulated and function was examined in human and animal models., [Findings] Here we demonstrate in a cohort of 816 subjects, 646 with biopsy-proven metabolic associated liver disease (MAFLD) and 170 controls, that duplication in the exportin 4 (XPO4) CNV is associated with the severity of liver fibrosis. Functionally, this occurs via reduced expression of hepatic XPO4 that maintains sustained activation of SMAD3/SMAD4 and promotes TGF-β1-mediated HSC activation and fibrosis. This effect was mediated through termination of nuclear SMAD3 signalling. XPO4 demonstrated preferential binding to SMAD3 compared to other SMADs and led to reduced SMAD3-mediated responses as shown by attenuation of TGFβ1 induced SMAD transcriptional activity, reductions in the recruitment of SMAD3 to target gene promoters following TGF-β1, as well as attenuation of SMAD3 phosphorylation and disturbed SMAD3/SMAD4 complex formation., [Interpretation] We conclude that a CNV in XPO4 is a critical mediator of fibrosis severity and can be exploited as a therapeutic target for liver fibrosis., ME and JG are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206) and Project and ideas grants (APP2001692, APP1107178 and APP1108422). AB is supported by an Australian Government Research Training Program (RTP) scholarship. EB is supported by Horizon 2020 under grant 634413 for the project EPoS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?

  • Lazarus, Jeffrey V.
  • Palayew, Adam
  • Carrieri, Patrizia
  • Ekstedt, Mattias
  • Marchesini, Giulio
  • Novak, Katja
  • Ratziu, Vlad
  • Romero-Gómez, Manuel
  • Tacke, Frank
  • Zelber-Sagi, Shira
  • Cortez-Pinto, Helena
  • Anstee, Quentin M.
[Background & Aims] Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent emerging condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to ensure that health systems can deliver effective care. We present a NAFLD Preparedness Index for Europe., [Methods] In June 2019, data were extracted by expert groups from 29 countries to complete a 41-item questionnaire about NAFLD. Questions were classified into 4 categories: policies/civil society (9 questions), guidelines (16 questions), epidemiology (4 questions), and care management (12 questions). Based on the responses, national preparedness for each indicator was classified into low, middle, or high-levels. We then applied a multiple correspondence analysis to obtain a standardised preparedness score for each country ranging from 0 to 100., [Results] The analysis estimated a summary factor that explained 71.3% of the variation in the dataset. No countries were found to have yet attained a high-level of preparedness. Currently, the UK (75.5) scored best, although falling within the mid-level preparedness band, followed by Spain (56.2), and Denmark (43.4), whereas Luxembourg and Ireland were the lowest scoring countries with a score of 4.9. Only Spain scored highly in the epidemiology indicator category, whereas the UK was the only country that scored highly for care management., [Conclusions] The NAFLD Preparedness Index indicates substantial variation between countries’ readiness to address NAFLD. Notably, even those countries that score relatively highly exhibit deficiencies in key domains, suggesting that structural changes are needed to optimise NAFLD management and ensure effective public health approaches are in place., [Lay summary] Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures aimed at preventing disease while also ensuring that health systems can deliver effective care to affected populations. This study defined preparedness as having adequate policies and civil society engagement, guidelines, epidemiology, and care management. NAFLD preparedness was found to be deficient in all 29 countries studied, with great variation among the countries and the 4 categories studied., The original data collection was funded by the EASL International Liver Foundation with support from Gilead Sciences Europe Ltd., Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, Pfizer Inc., and Resoundant Inc. The statistical analysis was funded by the EASL International Liver Foundation with support from Bristol-Myers-Squibb Company, Intercept, and Genfit. JVL is supported by a Spanish Ministry of Science, Innovation and Universities Miguel Servet grant (Instituto de Salud Carlos III/ESF, European Union [CP18/00074]) and further acknowledges institutional support from the Spanish Ministry of Science, Innovation and Universities through the ‘Centro de Excelencia Severo Ochoa 2019–2023’ Programme (CEX2018-000806-S), and support from the Government of Catalonia through the CERCA Programme. QMA and VR are members of the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413. QMA, VR, HCP, ME, and MRG are members of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the IMI2 Program of the European Union under Grant Agreement 777377. QMA is a Newcastle NIHR Biomedical Research Centre investigator. AP, PC, GM, KN, FT, and SZS have no financial support statements to disclose., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000806-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?

  • Younes, Ramy
  • Govaere, Olivier
  • Petta, Salvatore
  • Miele, Luca
  • Tiniakos, Dina
  • Burt, Alastair
  • Davis, Ezio
  • Vecchio, Fabio Maria
  • Maggioni, Marco
  • Cabibi, Daniela
  • McLeod, Duncan
  • Pareja, María Jesús
  • Fracanzani, Anna Ludovica
  • Aller, Rocío
  • Rosso, Chiara
  • Ampuero, Javier
  • Gallego-Durán, Rocío
  • Armandi, Angelo
  • Caviglia, Gian Paolo
  • Zaki, Marco Y. W.
  • Liguori, Antonio
  • Francione, Paolo
  • Pennisi, Grazia
  • Grieco, Antonio
  • Birolo, Giovanni
  • Fariselli, Piero
  • Eslam, Mohammed
  • Valenti, Luca
  • George, Jacob
  • Romero-Gómez, Manuel
  • Anstee, Quentin M.
  • Bugianesi, Elisabetta
[Objective] The full phenotypic expression of non-alcoholic fatty liver disease (NAFLD) in lean subjects is incompletely characterised. We aimed to investigate prevalence, characteristics and long-term prognosis of Caucasian lean subjects with NAFLD., [Design] The study cohort comprises 1339 biopsy-proven NAFLD subjects from four countries (Italy, UK, Spain and Australia), stratified into lean and non-lean (body mass index (BMI) </≥25 kg/m2). Liver/non-liver-related events and survival free of transplantation were recorded during the follow-up, compared by log-rank testing and reported by adjusted HR., [Results] Lean patients represented 14.4% of the cohort and were predominantly of Italian origin (89%). They had less severe histological disease (lean vs non-lean: non-alcoholic steatohepatitis 54.1% vs 71.2% p<0.001; advanced fibrosis 10.1% vs 25.2% p<0.001), lower prevalence of diabetes (9.2% vs 31.4%, p<0.001), but no significant differences in the prevalence of the PNPLA3 I148M variant (p=0.57). During a median follow-up of 94 months (>10 483 person-years), 4.7% of lean vs 7.7% of non-lean patients reported liver-related events (p=0.37). No difference in survival was observed compared with non-lean NAFLD (p=0.069)., [Conclusions] Caucasian lean subjects with NAFLD may progress to advanced liver disease, develop metabolic comorbidities and experience cardiovascular disease (CVD) as well as liver-related mortality, independent of longitudinal progression to obesity and PNPLA3 genotype. These patients represent one end of a wide spectrum of phenotypic expression of NAFLD where the disease manifests at lower overall BMI thresholds. [Lay summary] NAFLD may affect and progress in both obese and lean individuals. Lean subjects are predominantly males, have a younger age at diagnosis and are more prevalent in some geographic areas. During the follow-up, lean subjects can develop hepatic and extrahepatic disease, including metabolic comorbidities, in the absence of weight gain. These patients represent one end of a wide spectrum of phenotypic expression of NAFLD., This study has been supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413 and the Newcastle NIHR Biomedical Research Centre. The authors are contributing members of The European NAFLD Registry. The study was also supported by the Italian Ministry of Health, grant RF-2016-02364358 (Ricerca Finalizzata, Ministero della Salute). ME and JG are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206, APP1149976) and Project grants (APP1107178 and APP1108422)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impaired function of solute carrier family 19 leads to low folate levels and lipid droplet accumulation in hepatocytes

  • Cano, Ainara
  • Vazquez-Chantada, Mercedes
  • Conde-Vancells, Javier
  • Gonzalez-Lahera, Aintzane
  • Mosen-Ansorena, David
  • Blanco, Francisco J.
  • Cleḿent, Karine
  • Aron-Wisnewsky, Judith
  • Tran, Albert
  • Gual, Philippe
  • García-Monzón, Carmelo
  • Caballería, Joan
  • Castro, Azucena
  • Martínez-Chantar, María Luz
  • Mato, José M.
  • Zhu, Huiping
  • Finnell, Richard H.
  • Aransay, Ana M.
18 p.-5 fig.-2 tab., Low serum folate levels are inversely related to metabolic associated fatty liver disease (MAFLD). The role of the folate transporter gene (SLC19A1) was assessed to clarify its involvement in lipid accumulation during the onset of MAFLD in humans and in liver cells by genomic, transcriptomic, and metabolomic techniques. Genotypes of 3 SNPs in a case-control cohort were initially correlated to clinical and serum MAFLD markers. Subsequently, the expression of 84 key genes in response to the loss of SLC19A1 was evaluated with the aid of an RT2 profiler-array. After shRNA-silencing of SLC19A1 in THLE2 cells, folate and lipid levels were measured by ELISA and staining techniques, respectively. In addition, up to 482 amino acids and lipid metabolites were semi-quantified in SLC19A1-knockdown (KD) cells through ultra-high-performance liquid chromatography coupled with mass spectrometry. SNPs, rs1051266 and rs3788200, were significantly associated with the development of fatty liver for the single-marker allelic test. The minor alleles of these SNPs were associated with a 0.6/−1.67-fold decreased risk of developing MAFLD. When SLC19A1 was KD in THLE2 cells, intracellular folate content was four times lower than in wild-type cells. The lack of functional SLC19A1 provoked significant changes in the regulation of genes associated with lipid droplet accumulation within the cell and the onset of NAFLD. Metabolomic analyses showed a highly altered profile, where most of the species that accumulated in SLC19A1-KD-cells belong to the chemical groups of triacylglycerols, diacylglycerols, polyunsaturated fatty acids, and long chain, highly unsaturated cholesterol esters. In conclusion, the lack of SLC19A1 gene expression in hepatocytes affects the regulation of key genes for normal liver function, reduces intracellular folate levels, and impairs lipid metabolism, which entails lipid droplet accumulation in hepatocytes., This research was supported in part by CYTED 2005–2007 (FIT010000-2005-0013 to AC and AMA); La Caixa Foundation 2007–2009 (ID425 to MLM-CH and AMA); the «Programme Hospitalier de Reserche Clinique» Assistance Publique-Hôpitaux de Paris (AOR 02076); The Commission of the European Communities (Collaborative Project “Hepatic and adipose tissue and functions in the metabolic syndrome” HEPADIP, contract LSHM-CT-2005-018734); the European Union Seventh Framework Program (FP7/2007–2013, under grant agreement n° Health-F2-2009-241762, for the project FLIP and Horizon 2020 Framework Program (EPoS, grant #634413); Gobierno Vasco-Departamento de Salud 2013111114 (to MLM-C), MINECO: SAF2014-54658-R (to MLM-C), Instituto de Salud Carlos III: PIE/00031 (to MLM-C) and EITB Maratoia BIO15/CA/014 (to MLM-C); Basque Foundation for Health Innovation and Research and BBVA Foundation (to JMM, RHF). CTQ2017-83810-R and PID2020-113225GB-I00 from MINECO to FJB; and The Instituto de Salud Carlos III, Spain grants 13/01299 and 17/00535 co-funded with European FEDER funds (to CG-M). This work was also funded by the French Government (National Research Agency, ANR, #ANR-15-CE14-0016-0), INSERM (France) and Association Française pour l’Etude du Foie (AFEF). CIBERehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. CIC bioGUNE support was provided from The Department of Industry, Tourism and Trade of the Government of the Autonomous Community of the Basque Country (Etortek, Emaitek and Elkartek Research Programs 2005–2021), the Innovation Technology Department of the Bizkaia County and MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

P465L pparγ mutation confers partial resistance to the hypolipidemic action of fibrates.

  • Rodriguez Cuenca, Sergio
  • Carobbio, Stefania
  • Barceló-Coblijn, Gwendolyn
  • Prieur, Xavier
  • Relat Pardo, Joana
  • Amat, Ramon
  • Campbell, Mark
  • Dias, Ana Rita
  • Bahri, Myriam
  • Gray, Sarah L.
  • Vidal-Puig, Antonio
Familial partial lipodystrophic syndrome 3 (FPLD3) is associated with mutations in the transcription factor PPAR. The P467L mutant confers a dominant negative effect. We have previously investigated the pathophysiology of FPLD3 using a humanised mouse harbouring an equivalent mutation (P465L) in PPAR that recapitulated the human clinical phenotype. One of the key clinical manifestations observed in humans and mice is the accumulation of fat in the liver. Here, we dissect the molecular mechanisms that facilitate accumulation of lipids in the liver and characterise the negative effect of the PPAR mutation on the activation of PPAR in vivo by fibrates. P465L mice have increased insulin and FFAs, decreased secretion of VLDL when fed HFD and impaired hypolipidemic response to WY14643. Thus, the phenotype of PPAR mutations may synergise with defects on PPAR function, indicating that the phenotype of the FPLD3 patients may not only be attributed to the dysfunction of PPAR.